Professor David Chang

Professor of Surgical Oncology (Clinical Research Garscube)

telephone: 01413307589
email: David.Chang@glasgow.ac.uk

Wolfson Wohl Cancer Research Centre, Garscube Estate, Switchback Road, Glasgow, G61 1QH

Biography

David is a surgeon scientist who specialises in the treatment of malignant pancreatic diseases. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer, particularly around DNA-damage response deficiency, by utilising molecular biomarkers of prognosis and therapeutic responsiveness. David undertook his pancreatic surgical fellowship, PhD, and post-doctoral training in Australia. In 2013 he was recruited to University of Glasgow along with Prof Andrew Biankin, as part of an initiative to implement precision medicine in West of Scotland and the UK. David co-leads Precision-Panc, a pan-UK initiative to deliver personalised cancer care for pancreatic cancer, and is the chief investigator of its Master Protocol and the first inter-related clinical trials. He is also involved in the Precision Promise initiative, a Pancreatic Cancer Action Network (USA) initiative dedicated in delivering personalized treatment for patients with pancreatic cancer, and contributes to ICGC ARGO, aiming to shape the future of the next generation cancer genomic projects to ultimately realise the goals and promises of precision medicine.

Clinically, David is an Honorary Consultant Pancreatic Surgeon at Glasgow Royal Infirmary as part of the West of Scotland Pancreatic Unit that serves as tertiary pancreatic referral centre for the West of Scotland. His research aims to shorten the distance between the bench and the clinic to ensure meaningful and seamless translation between the two.

Research interests

David Chang is a surgeon-scientist dedicated to management and research in the field of pancreatic cancer and the delivery of stratified cancer care. His main research focus is the development and implementation of stratified medicine through molecular phenotyping using both tissue- and genomic-based assays.

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2004 | 2003

Number of items: 112.

2024

McGuigan, M.-C., Hadjicosti, R., Cameron, A. J. , Coats, M., Chang, D. , Dickson, E. J., Holroyd, D., McKay, C. J. and Jamieson, N. B. (2024) The surveillance strategy for Intraductal Pancreatic Mucinous Neoplasms: Criteria for discontinuation. Annals of Surgery, (doi: 10.1097/SLA.0000000000006580) (PMID:39480643) (Accepted for Publication)

Boey, A., Bryce, A. , Dickson, E., Coats, M., McKay, C., Jamieson, N. , Chang, D. , Holroyd, D. and Dreyer, S. (2024) The Impact of Pre-operative Indeterminate Lung Nodules in the Surgical Management of Pancreatic Ductal Adenocarcinoma. 16th World Congress of the International Hepato-Pancreato-Biliary Association, Cape Town, South Africa, 15-18 May 2024. S148. (doi: 10.1016/j.hpb.2024.03.269)

Cooke, S. F. et al. (2024) Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC. Scientific Reports, 14, 8998. (doi: 10.1038/s41598-024-59451-3) (PMID:38637546)

Zhang, S. et al. (2024) Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Cell Death Discovery, 10, 124. (doi: 10.1038/s41420-024-01890-y) (PMID:38461159) (PMCID:PMC10924943)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)

Riviere, D., Aarntzen, E., van Geenen, E., Chang, D. , de Geus-Oei, L.-F., Brosens, L., van Laarhoven, K., Gotthardt, M. and Hermans, J. (2024) Qualitative flow metabolic phenotype of pancreatic cancer: a new prognostic biomarker? HPB, 26(3), pp. 389-399. (doi: 10.1016/j.hpb.2023.11.010) (PMID:38114400)

Bryce, A. , Dreyer, S., Dolan, R. , Froeling, F. and Chang, D. (2024) Host phenotypic adversity independently predicts progression to resection in neoadjuvantly-treated pancreatic cancer. 42nd Congress of the European Society of Surgical Oncology, Florence, Italy, 25-27 Oct 2023. (doi: 10.1016/j.ejso.2023.107753)

Dreyer, S., Bryce, A. , Australian Pancreatic Cancer Genome Initiative, , Biankin, A. , Jamieson, N. and Chang, D. (2024) The clinical and molecular landscape of early onset pancreatic cancer. 42nd Congress of the European Society of Surgical Oncology, Florence, Italy, 25-27 Oct 2023. (doi: 10.1016/j.ejso.2023.107348)

2023

McGovern, J., Leadbitter, S., Miller, G., Hounat, A., Kamande, I., Dolan, R. D. , Horgan, P. G. , Chang, D. K. , Jamieson, N. B. and McMillan, D. C. (2023) The relationship between heart rate variability and TNM stage, co-morbidity, systemic inflammation and survival in patients with primary operable colorectal cancer. Scientific Reports, 13, 8157. (doi: 10.1038/s41598-023-35396-x) (PMID:37208421) (PMCID:PMC10198985)

Dreyer, S. B. et al. (2023) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, 277(2), e396-e405. (doi: 10.1097/SLA.0000000000005050) (PMID:36745763) (PMCID:PMC9831035)

2022

Ali, A. et al. (2022) Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. American Journal of Cancer Research, 12(12), pp. 5668-5683. (PMID:36628279) (PMCID:PMC9827095)

Bryce, A. S. , Dreyer, S. B., Froeling, F. E.M. and Chang, D. K. (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. (doi: 10.3390/cancers14215302) (PMID:36358721) (PMCID:PMC9659154)

Pennel, K. A. F. et al. (2022) CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer. Journal of Pathology: Clinical Research, 8(6), pp. 509-520. (doi: 10.1002/cjp2.290) (PMID:35879507) (PMCID:PMC9535100)

Zeng, S. et al. (2022) CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 41, 241. (doi: 10.1186/s13046-022-02443-w) (PMID:35945614) (PMCID:PMC9364549)

Patel, M. et al. (2022) Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 126(12), pp. 1704-1714. (doi: 10.1038/s41416-022-01729-2) (PMID:35173303) (PMCID:PMC9174220)

Dreyer, S. B., Upstill-Goddard, R., Legrini, A. , Biankin, A. V. , Jamieson, N. B. and Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162(1), 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022) (PMID:34534536) (PMCID:PMC8721486)

Dreyer, S., Upstill-Goddard, R., Legrini, A. , Biankin, A. , Jamieson, N. and Chang, D. (2022) Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. 15th World Congress of the International Hepato-Pancreato-Biliary Association, New York, USA, 30 Mar - 02 Apr 2022. S44-S45. (doi: 10.1016/j.hpb.2022.05.086)

2021

Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Schwappacher, R. et al. (2021) Muscle-derived cytokines reduce growth, viability and migratory activity of pancreatic cancer cells. Cancers, 13(15), 3820. (doi: 10.3390/cancers13153820)

Vivekanandhan, S. et al. (2021) Role of PLEXIND1/TGFβ signaling axis in pancreatic ductal adenocarcinoma progression correlates with the mutational status of KRAS. Cancers, 13(16), 4048. (doi: 10.3390/cancers13164048)

Lakis, V. et al. (2021) DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4, 155. (doi: 10.1038/s42003-020-01469-0) (PMID:33536587) (PMCID:PMC7859232)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)

2020

Miller, R.E. et al. (2020) ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 31(12), pp. 1606-1622. (doi: 10.1016/j.annonc.2020.08.2102) (PMID:33004253)

Beer, P. A., Cooke, S. L. , Chang, D. K. and Biankin, A. V. (2020) Defining the clinical genomic landscape for real-world precision oncology. Genomics, 112(6), pp. 5324-5330. (doi: 10.1016/j.ygeno.2020.10.032) (PMID:33144218) (PMCID:PMC7758710)

Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, 4748. (doi: 10.1038/s41467-020-18151-y) (PMID:32958763) (PMCID:PMC7505971)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, 4330. (doi: 10.1038/s41467-020-17359-2) (PMID:32859912) (PMCID:PMC7455744)

Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272(2), pp. 366-376. (doi: 10.1097/SLA.0000000000003143) (PMID:32675551) (PMCID:PMC7373491)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, et al. (2020) Pan-cancer analysis of whole genomes. Nature, 578(7793), pp. 82-93. (doi: 10.1038/s41586-020-1969-6) (PMID:32025007) (PMCID:PMC7025898)

Jiao, W. et al. (2020) A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature Communications, 11, 728. (doi: 10.1038/s41467-019-13825-8) (PMID:32024849) (PMCID:PMC7002586)

Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K. (2020) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, 32(1), pp. 1-4. (doi: 10.1016/j.clon.2019.07.011) (PMID:31378449)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32(1), pp. 5-8. (doi: 10.1016/j.clon.2019.08.007) (PMID:31522943)

2019

Beer, P. A., Cooke, S. L. , Chang, D. K. and Biankin, A. V. (2019) Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. Annals of Oncology, 30(11), pp. 1691-1694. (doi: 10.1093/annonc/mdz392) (PMID:31665210)

Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, 3637. (doi: 10.1038/s41467-019-10968-6) (PMID:31406163) (PMCID:PMC6691013)

Reader, C. S. et al. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 249(3), pp. 332-342. (doi: 10.1002/path.5320) (PMID:31259422) (PMCID:PMC6852434)

Halbrook, C. J. et al. (2019) Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabolism, 29(6), 1390-1399.e6. (doi: 10.1016/j.cmet.2019.02.001) (PMID:30827862) (PMCID:PMC6602533)

Collisson, E. A., Bailey, P. , Chang, D. K. and Biankin, A. V. (2019) Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 16, pp. 207-220. (doi: 10.1038/s41575-019-0109-y) (PMID:30718832)

2018

Chou, A. et al. (2018) Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 67(12), pp. 2142-2155. (doi: 10.1136/gutjnl-2017-315144) (PMID:29080858) (PMCID:PMC6241608)

Veenstra, V.L. et al. (2018) ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis, 7, 87. (doi: 10.1038/s41389-018-0096-9) (PMID:30442938) (PMCID:PMC6237826)

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi: 10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

2017

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi: 10.1038/nature24462) (PMID:29132146) (PMCID:PMC6145146)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi: 10.1038/nature24026) (PMID:28953865)

Raphael, B. J. et al. (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell, 32(2), 185-203.e13. (doi: 10.1016/j.ccell.2017.07.007) (PMID:28810144) (PMCID:PMC5964983)

Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi: 10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)

Feigin, M. E. et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 49(6), pp. 825-833. (doi: 10.1038/ng.3861) (PMID:28481342) (PMCID:PMC5659388)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi: 10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)

Dreyer, S. B., Chang, D. K. , Bailey, P. and Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23(7), pp. 1638-1646. (doi: 10.1158/1078-0432.CCR-16-2411) (PMID:28373362)

Pishvaian, M. J., Biankin, A. V. , Bailey, P. , Chang, D. K. , Laheru, D., Wolfgang, C. L. and Brody, J. R. (2017) BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer, 116, pp. 1021-1026. (doi: 10.1038/bjc.2017.40) (PMID:28291774)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi: 10.1038/nature21063) (PMID:28199314)

Vallejo, A. et al. (2017) An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 8, 14294. (doi: 10.1038/ncomms14294) (PMID:28220783) (PMCID:PMC5321758)

Byrne, A. T. et al. (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 17, pp. 254-268. (doi: 10.1038/nrc.2016.140) (PMID:28104906)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060) (PMID:27856273)

2016

Roy, N. et al. (2016) PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Genes and Development, 30(24), pp. 2669-2683. (doi: 10.1101/gad.291021.116) (PMID:28087712)

Bailey, P. et al. (2016) Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 6, 35848. (doi: 10.1038/srep35848) (PMID:27762323) (PMCID:PMC5071896)

Humphrey, E. S. et al. (2016) Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Molecular and Cellular Proteomics, 15(8), pp. 2671-2685. (doi: 10.1074/mcp.M116.058313) (PMID:27259358) (PMCID:PMC4974343)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi: 10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Chen, Y., Awan, N., Haveman, J. W., Apostolou, C., Chang, D. K. and Merrett, N. D. (2016) Gastric cancer: Australian outcomes of multi-modality treatment with curative intent. ANZ Journal of Surgery, 86(5), pp. 386-390. (doi: 10.1111/ans.12693) (PMID:24846566)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)

Gingras, M.-C. et al. (2016) Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Reports, 14(4), pp. 907-919. (doi: 10.1016/j.celrep.2015.12.005) (PMID:26804919) (PMCID:PMC4982376)

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi: 10.1097/PAI.0000000000000357) (PMID:27093449)

2015

Moran-Jones, K. et al. (2015) Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 6(42), pp. 44551-44562. (doi: 10.18632/oncotarget.6082) (PMID:26575166) (PMCID:PMC4792575)

Jamieson, N. B. , Chang, D. K. and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi: 10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B. , Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi: 10.1111/cge.12536) (PMID:25388820)

Chantrill, L.A. et al. (2015) Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clinical Cancer Research, 21(9), pp. 2029-2037. (doi: 10.1158/1078-0432.CCR-15-0426) (PMID:25896973)

Susanto, J. M. et al. (2015) The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. International Journal of Oncology, 46(5), pp. 2223-30. (doi: 10.3892/ijo.2015.2894) (PMID:25695794)

Chen, Y., Haveman, J. W., Apostolou, C., Chang, D. K. and Merrett, N. D. (2015) Asian gastric cancer patients show superior survival: the experiences of a single Australian center. Gastric Cancer, 18(2), pp. 256-261. (doi: 10.1007/s10120-014-0383-x) (PMID:24858392)

Humphris, J., Chang, D. K. and Biankin, A. V. (2015) Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. Gastroenterology, 148(3), pp. 496-498. (doi: 10.1053/j.gastro.2015.01.009) (PMID:25613311)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi: 10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi: 10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

2014

Humphris, J. L. et al. (2014) Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), pp. 3669-3675. (doi: 10.1002/cncr.28863) (PMID:25313458)

Nones, K. et al. (2014) Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. International Journal of Cancer, 135(5), pp. 1110-1118. (doi: 10.1002/ijc.28765) (PMID:24500968)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi: 10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Sjoquist, K. M. et al. (2014) Personalising pancreas cancer treatment: when tissue is the issue. World Journal of Gastroenterology, 20(24), pp. 7849-7863. (doi: 10.3748/wjg.v20.i24.7849) (PMID:24976722) (PMCID:PMC4069313)

Johns, A. L. et al. (2014) Returning individual research results for genome sequences of pancreatic cancer. Genome Medicine, 6(5), 42. (doi: 10.1186/gm558) (PMID:24963353) (PMCID:PMC4067993)

Jamieson, N. B. , Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi: 10.1586/17474124.2014.893820) (PMID:24702631)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Pancreatic cancer genomics. Current Opinion in Genetics and Development, 24, pp. 74-81. (doi: 10.1016/j.gde.2013.12.001) (PMID:24480245)

Nagrial, A.M. et al. (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), pp. 313-319. (doi: 10.1038/bjc.2013.722) (PMID:24263063) (PMCID:PMC3899761)

Chang, D. K. , Grimmond, S. M., Evans, T. R.J. and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi: 10.1038/nrc3723) (PMID:25688402)

Chang, D. K. , Jamieson, N. B. , Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, Sandosh (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi: 10.1016/B978-0-12-386882-4.00034-7)

Jamieson, N. B. , Grimmond, S. M., Biankin, A. V. and Chang, D. K. (2014) Pancreatic cancer: Challenges for therapeutic development. In: Scarlett, Christopher J. and Vuong, Quan V. (eds.) Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. Nova Science, pp. 1-28. ISBN 9781634633246

2013

Kassahn, K. S. et al. (2013) Somatic point mutation calling in low cellularity tumors. PLoS ONE, 8(11), e74380. (doi: 10.1371/journal.pone.0074380) (PMID:24250782) (PMCID:PMC3826759)

Chang, D. K. , Jamieson, N. B. , Scarpa, A., McKay, C. J. and Biankin, A. V. (2013) Reply to G.F. Arroyo. Journal of Clinical Oncology, 31(30), pp. 3843-3844. (doi: 10.1200/JCO.2013.51.3176) (PMID:24043730)

Cowley, M.J., Chang, D.K. , Pajic, M., Johns, A.L., Waddell, N., Grimmond, S.M. and Biankin, A.V. (2013) Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 20(6), pp. 549-556. (doi: 10.1007/s00534-013-0610-6) (PMID:23660961)

Cao, Y. et al. (2013) Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial 5 integrin. Cancer Research, 73(14), pp. 4579-4590. (doi: 10.1158/0008-5472.CAN-13-0529) (PMID:23689123) (PMCID:PMC3774599)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi: 10.1200/JCO.2012.46.8868) (PMID:23439753)

Chou, A. et al. (2013) Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), p. 78. (doi: 10.1186/gm482) (PMID:24004612) (PMCID:PMC3978667)

Liu, P.Y. et al. (2013) The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death and Differentiation, 20(3), pp. 503-514. (doi: 10.1038/cdd.2012.147) (PMID:23175188) (PMCID:PMC3569991)

2012

Biankin, A.V. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), pp. 399-405. (doi: 10.1038/nature11547) (PMID:23103869) (PMCID:PMC3530898)

Tactacan, C. M. et al. (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 12(1), 395. (doi: 10.1186/1471-2407-12-395) (PMID:22958871) (PMCID:PMC3532183)

Pérez-Mancera, P.A. et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402), pp. 266-270. (doi: 10.1038/nature11114)

Humphris, J.L. et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), pp. 1713-1722. (doi: 10.1093/annonc/mdr561) (PMID:22241899) (PMCID:PMC3387824)

Mann, K. M. et al. (2012) Inaugural article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(16), pp. 5934-5941. (doi: 10.1073/pnas.1202490109) (PMID:2242144) (PMCID:PMC1663246)

2011

Colvin, E.K. et al. (2011) Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS ONE, 6(12), e29075. (doi: 10.1371/journal.pone.0029075) (PMID:22220202) (PMCID:PMC3248409)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2011) Molecular diagnostics in pancreatic cancer. In: Friess, Helmut and Hüser, Norbert (eds.) Advances in Pancreatic Cancer Treatment. Future Medicine Ltd., pp. 20-35. ISBN 9781780840703 (doi: 10.2217/EBO.11.330)

Scarlett, C. J. et al. (2011) Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS ONE, 6(10), e26088. (doi: 10.1371/journal.pone.0026088) (PMID:22022519) (PMCID:PMC3193536)

Pajic, M., Scarlett, C. J., Chang, D. K. , Sutherland, R. L. and Biankin, A. V. (2011) Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Human Genetics, 130(1), pp. 93-101. (doi: 10.1007/s00439-011-0990-0) (PMID:21516344)

Nguyen, N. Q. et al. (2011) Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. Journal of Gastroenterology and Hepatology, 26(2), pp. 267-274. (doi: 10.1111/j.1440-1746.2010.06466.x) (PMID:21261715)

2010

Marshall, G.M. et al. (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene, 29(44), pp. 5957-5968. (doi: 10.1038/onc.2010.332) (PMID:20697349)

2009

Leong, R. W.L., Chang, D. , Merrett, N. D. and Biankin, A. V. (2009) Taking optical biopsies with confocal endomicroscopy. Journal of Gastroenterology and Hepatology, 24(11), pp. 1701-1703. (doi: 10.1111/j.1440-1746.2009.06011.x) (PMID:20136953)

Chang, D.K. et al. (2009) Margin clearance and outcome in resected pancreatic cancer. Journal of Clinical Oncology, 27(17), pp. 2855-2862. (doi: 10.1200/JCO.2008.20.5104) (PMID:19398572)

Nguyen, N. Q., Biankin, A. V. , Leong, R. W. L., Chang, D. K. , Cosman, P. H., Delaney, P., Kench, J. G. and Merrett, N. D. (2009) Real time intraoperative confocal laser microscopy-guided surgery. Annals of Surgery, 249(5), pp. 735-737. (doi: 10.1097/SLA.0b013e3181a38f11) (PMID:19387332)

Gill, A. J. et al. (2009) Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology, 41(2), pp. 161-167. (doi: 10.1080/00313020802337329) (PMID:19320058)

Biankin, A.V. et al. (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology, 137(2), 558-568.e11. (doi: 10.1053/j.gastro.2009.04.009) (PMID:19376121)

Chang, D. K. , Nguyen, N. Q., Merrett, N. D., Dixson, H., Leong, R. W.L. and Biankin, A. V. (2009) Role of endoscopic ultrasound in pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 3(3), pp. 293-303. (doi: 10.1586/egh.09.18) (PMID:19485810)

2008

Colvin, E. K., Chang, D. K. , Merrett, N. D., Kench, J. G. and Biankin, A. V. (2008) Individualizing therapy for pancreatic cancer. Journal of Gastroenterology and Hepatology, 23(12), pp. 1779-1782. (doi: 10.1111/j.1440-1746.2008.05683.x) (PMID:19120869)

Das, A., Chang, D. , Biankin, A. V. and Merrett, N. D. (2008) Pancreatitis following human papillomavirus vaccination. Medical Journal of Australia, 189(3), p. 178. (doi: 10.5694/j.1326-5377.2008.tb01960.x) (PMID:18673112)

Chang, D. K. , Merrett, N. D. and Biankin, A. V. (2008) Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem? Journal of Gastroenterology and Hepatology, 23(7pt1), pp. 1036-1045. (doi: 10.1111/j.1440-1746.2008.05471.x) (PMID:18707598)

2004

Chang, D. K. and Ross, W. B. (2004) Endoscopic retrieval of a teaspoon from the stomach. ANZ Journal of Surgery, 74(11), pp. 1013-1014. (doi: 10.1111/j.1445-1433.2004.03224.x) (PMID:15550094)

2003

Shi, L.W., Verran, D., Chang, D. , Drenckhahn, C., Fisher, J., Stewart, G. and McCaughan, G. (2003) Primary liver transplantation with preexisting portal vein thrombosis. Transplantation Proceedings, 35(1), pp. 354-355. (doi: 10.1016/S0041-1345(02)04020-4) (PMID:12591437)

This list was generated on Sat Apr 19 13:36:55 2025 BST.

Jump to: Articles | Book Sections | Conference or Workshop Item